Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents

Department of Psychiatry and Pharmacology, Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
JAMA Pediatrics (Impact Factor: 4.25). 11/2008; 162(10):929-35. DOI: 10.1001/archpedi.162.10.929
Source: PubMed

ABSTRACT To identify factors associated with incident cardiovascular events and metabolic disturbance in children and adolescents treated with antipsychotics.
A retrospective cohort design evaluating Medicaid medical and pharmacy claims.
South Carolina's Medicaid program covering outpatient and inpatient medical services and medication prescriptions from January 1, 1996, through December 31, 2005.
A treatment cohort of 4140 children and adolescents prescribed 1 of 5 atypical or 2 conventional antipsychotics, and a random sample of 4500 children not treated with psychotropic medications. Main Exposure Antipsychotics.
Incidence/prevalence rates for obesity, type 2 diabetes mellitus, dyslipidemia, cardiovascular events, cerebrovascular events, hypertension, and orthostatic hypotension.
Compared with the control sample, the treated cohort had a higher prevalence of obesity (odds ratio [OR], 2.13), type 2 diabetes mellitus (OR, 3.23), cardiovascular conditions (OR, 2.70), and orthostatic hypotension (OR, 1.64). In the treated cohort, patients exposed to multiple antipsychotics were at significantly higher risk for incident obesity/weight gain (OR, 2.28), type 2 diabetes mellitus (OR, 2.36), and dyslipidemia (OR, 5.26). Incident cardiovascular events were more likely with the use of conventional (OR, 4.34) or multiple (OR, 1.57) antipsychotics and mood stabilizers (OR, 1.31). Incident orthostatic hypotension was more prevalent in those coprescribed selective serotonin reuptake inhibitors (OR, 1.77) and mood stabilizers (OR, 1.35).
Antipsychotics are associated with several metabolic and cardiovascular-related adverse events in pediatric populations, especially when multiple antipsychotics or classes of psychotropic medications are coprescribed, controlling for individual risk factors.


Available from: Jeanette M Jerrell, Oct 16, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There has been a growth in the knowledge about autism and autism spectrum disorders (ASD) in the United States and worldwide. As the prevalence rates have grown, so has the awareness of the need to develop effective and safe treatments for children with ASD. In addition to the behavioral interventions such as applied behavioral analysis, parent training, and adaptive skills training, there has been an increase in the use of medications for the treatment of ASD symptoms. At this time, there are two antipsychotics approved by the FDA for the use in children with ASD, risperidone and aripiprazol. Generally, the use of this classification has been more recently associated with changes in metabolic function in children. The purpose of this article is to review briefly the use of psychotropic medications, focusing on antipsychotics, and discuss the metabolic risks and risk factors associated with their use within children with autism. [N A J Med Sci. 2012;5(3): 162-166.] Key Words: autism, autism spectrum disorders (ASD), antipsychotics, metabolic syndrome, treatment and management of autism INTRODUCTION Autism and autism spectrum disorders (ASD) are neurodevelopmental disorders that cause impairments in social interactions and communication. In addition, ASD can manifests with symptoms of irritability, cognitive rigidity, stereotyped/restricted patterns of behavior, and often aggression. Although symptoms are usually present from the age of 3, there is increasing evidence that there is a wide range of impairments within children and adolescents leading to wide variation in the long-term impact of ASD on quality of life. Since 1943, when Kanner originally described and coined the term "autism", there have been huge advancements in autism research and the awareness of ASD. 1 A recent study published by the Autism Developmental Disabilities Monitoring Network in the US estimated the prevalence across 14 sites to be 11.3 per 1,000 (1/88). 2 Additionally, a 2012 report on the global prevalence of autism and ASD reported a lower prevalence rate of 62 per 10,000 and stated, "while existing estimates are variable, the evidence reviewed does not support differences in PDD prevalence by geographic region nor a strong impact of ethnic/cultural or socioeconomic factors". 3 Regardless, there have been great advancements in the development of diagnostic tools to identify and distinguish children with ASD, allowing us to further our understanding about the disorder and develop ways to treat and manage symptoms related to ASD.
    North American journal of medicine & science 01/2012; 5(3). DOI:10.7156/v5i3p162
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article examined the continuity of atypical antipsychotic medications among children and adolescents following discharge from a residential mental health treatment facility in the state of Florida from 2005 through 2011. Discharge data are reported by the residential providers, while post-discharge data are from Medicaid enrollment and claims files. Fifty-five percent of youth were receiving antipsychotic medications when discharged from residential treatment. Of those receiving such medications, 55% continued with their medication after discharge. Antipsychotics were more likely at discharge among youth who were older, had longer treatment episodes, showed greater improvements during treatment, and had prior involuntary examinations and out-of-home treatment episodes. Continuation of antipsychotic medication was more common among youth who had greater family involvement in treatment, longer treatment episodes, improved more during treatment, and had prior involuntary examinations. Continuation was less likely for youth with prior out-of-home treatment episodes. These results contribute to the existing literature by examining the continuity of atypical antipsychotic medication among children and adolescents following residential treatment.
    Residential Treatment for Children & Youth 10/2013; 30(4):306-318. DOI:10.1080/0886571X.2013.852455
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Glucose dysregulation and type 2 diabetes mellitus (T2DM) are feared antipsychotic drug adverse effects. Despite increasing utilization, data about antipsychotic risk of T2DM in youth are scarce. Areas covered: We conducted a systematic PubMed/MEDLINE search until 15 May 2014 focusing on studies with ≥ 20 youths aged ≤ 24 years, reporting quantitative data on: i) change in fasting glucose, hemoglobin A1c, insulin or insulin resistance after antipsychotic initiation (studies = 19, n = 2123,age = 13.3 years, follow up = 28.8 weeks); or ii) prevalence (studies = 4) or incidence (studies = 8, follow up = 1.57 years) of T2DM in antipsychotic-exposed youth (studies = 10, n = 65,486, age = 14.2 years) versus healthy controls (studies = 4, n = 246,828), psychiatric controls (studies = 5, n = 61,784) or without control groups (studies = 2). Expert opinion: Antipsychotics are associated with early adverse changes in glucose metabolism that are greater with all analyzable antipsychotics compared to controls, being highest with olanzapine, followed by quetiapine, aripiprazole and risperidone; but data were scarce. Although T2DM is fortunately rare in antipsychotic-treated youth, its prevalence (odds ratio [OR] = 8.176, 95% CI = 7.139 - 9.362) and incidence (OR = 1.450, 95% CI = 1.101 - 1.911, p = 0.006) were higher than in healthy controls. Similarly, T2DM prevalence (OR = 3.475, 95% CI = 3.019 - 4.001, p < 0.0001) and incidence (OR = 5.376, 95% CI = 4.004 - 7.233, p < 0.0001, excluding one outlying study) were higher than in psychiatric controls. Antipsychotics should only be used after lower-risk interventions failed, and inappropriately low clinical metabolic monitoring must be remedied.
    Expert Opinion on Drug Safety 12/2014; 14(2):1-23. DOI:10.1517/14740338.2015.979150 · 2.74 Impact Factor